• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    Composition of 4-methylimidazole for use in the cure of diseases, regeneration of tissues in the human body and "very specific internal treatments", by means of catheters, probes or cannulas provided with devices "that can supply a composition" in biofilms and pathogenic zones. (Machine-translation by Google Translate, not legally binding)
    公开号:ES2685077A1
    申请号:ES201700370
    申请日:2017-03-31
    公开日:2018-10-05
    发明作者:José Luis GONZÁLEZ DÍEZ
    申请人:José Luis GONZÁLEZ DÍEZ；
    IPC主号:
    专利说明:

    DESCRIPTION

    Composition of 4-methylimidazole for use in the cure of diseases.

    Technical sector 5

    The present invention belongs to the technical medicine sector. In particular, the invention relates to a specific composition for use in the cure of diseases and regeneration of human body tissues.
     10
    Background of the invention

    1.1 Presentation

    Antibiotic resistance has become a worldwide reality. Diseases that were hitherto treated easily with antibiotics could now become lethal. The causes, multiple. Although antibiotics are used correctly, resistance can still occur. This is because almost all antibiotics are based on molecules that the microbes themselves use to fight with each other, thus the bacteria carry with them self-defense resistance genes. Actually, scientists show us that antibiotic resistance goes back to Prehistory.

    In its report of April 30, 2014, the World Health Organization (WHO) makes a worrying study on the matter. The report shows the resistance that the bacterium Klebsiella pneumoniae presents to antibiotic treatment. Fluoroquinolones, widely used in urinary tract infections, are now ineffective in half of patients. In gonococcal infections, which causes blenorrhagia, treatment with cephalosporins has also failed. Likewise, Staphylococcus aureus infections, tuberculosis, malaria and HIV are also affected in this regard, due to the resistance they present to medications. 30

    WHO regrets that surveillance of antimicrobial resistance is not coordinated or harmonized. Therefore, WHO launches in this report a global plan of action on antibiotic resistance.
     35
    Hence the importance of solving the problems posed by infection processes. There is an extensive bibliography and guidelines for antimicrobial therapy, which generally address this issue in a different line from the one we propose here.

    Description of the invention 40

    2.1 Composition

    4-methylimidazole (4-MEI)
     Four. Five
    Foods containing caramel dye have been consumed in many homes for centuries, and also, more recently, this dye has been incorporated into new foods and beverages that are part of our current foods. We have verified that some of these food products have healing properties against certain diseases. fifty

    4-methylimidazole (4-MEI), is not a substance that is found in our environment naturally but is produced when caramel dye is made, which is incorporated into
    Foods that contain this dye. This substance can be produced during food cooking. In reduced consumption there are no side effects.

    Therefore, the use of 4-methylimidazole (4-MEI), of chemical formula C4H6N2, molecular weight 82.11, has been proposed to manufacture a medication for the treatment of flu and colds, 5 urinary infections and inflammations, among other diseases, and even as a preventive means.

    There is no international unanimity to establish a definition that allows setting the maximum limit of 4-MEI for human consumption. The FDA, 10 European Commission and Codex regulatory specifications allow such foods and beverages to contain up to 250 ppm of 4-MEI. The United States National Program conducted rigorous studies of the health effects of 2-MEI and 4-MEI, and found that 4-MEI could be carcinogenic if consumed in large total amounts.
     fifteen
    The 4-MEI was nominated by the National Cancer Institute of the United States to conduct an in-depth study because of the high potential for human exposure. F344 / N male and female rats and B6C3F-1 male and female mice were exposed to 4-MEI (99.5% pure) in feed for two years. Toxicity studies were reported in the NTP Toxicity Report No. 67. Genetic toxicology studies were also conducted. twenty

    The study in rats was performed with groups of 50 males and 50 females that were fed diets containing 0.625, 1 250, or 2,500 ppm of 4-MEI (males) or, 0, 1 250, 2,500, or 5,000 ppm of 4-MEI (females) (equivalent to an average daily dose of approximately 30, 55, or 115 mg of 4-MEI / kg of body weight in males and 60. 120, or 260 mg / kg in the 25 females) for 106 weeks.

    The study in mice was conducted with groups of 50 males and 50 females that were fed diets containing 0. 312, 625, or 1 250 ppm of 4-MEI (equivalent to an average daily dose of approximately 40, 80, and 170 4-MEI mg / kg body weight 30 in males and females) for 106 weeks.

    The findings of NTP indicate that under the conditions of these studies conducted over two years, there is no evidence of carcinogenic activity of 4-MEI in male F344 / N rats exposed to 625, 1 250, or 2,500 ppm. There is equivocal evidence of carcinogenic activity of 4-MEI in female F344 / N rats. There is clear evidence of carcinogenic activity of 4-MEI in male and female B6C3F-1 mice. Exposure to 4-MEI has not resulted in neoplastic lesions in the liver of male and female rats and in the lungs of female mice and in clinical findings of neurotoxicity in female rats.
     40
    In 2011, the European Food Safety Authority (EFSA) assessed the risk of 4-MEI for the use of caramel dyes and concluded that human exposure to 4-MEI in Europe was well below the threshold level reflected in the NTP study. In 2012, EFSA reassessed consumer exposure to 4-MEI by the use of caramel dyes, and reaffirmed its 2011 conclusion. EFSA also noted that 4-MEI does not appear to cause DNA mutations 45 (genotoxicity) and that The type of tumors observed in mice in the NTP study may occur spontaneously in these animals. For these reasons, EFSA has concluded that they are not concerned about the exposure of Europeans to 4-MEI by the use of caramel dyes in food.
     fifty
    We have selected 4-MEI because it has been shown to have positive behavior for use as a medicine against bacteria and viruses. This prevents the proliferation of these pathogens in the human body.
    Many researchers have shown great interest in derivatives of the imidazole nucleus for its biological diversity and clinical applications, but much of their work has been directed towards the study of more complicated formulations than we propose, and in most cases They have great toxicity. Research work has been carried out for its use as anticancer, antiviral, anti-HIV, antiprotozoal, antimicobacterial, 5 anti-inflammatory, analgesic, anxiolytic, and antidiabetic agents, among others (B. Narasimhan, et al., Medical Chemistry Research. Copyright Springer Science + Business Media, LLC 2010).

    Honey
     10
    Composition

    Being a natural product the composition of honey is highly variable. In the document “Definition of Honey and Honey Products,” Approved by the National Honey Board June 15, 1996, Updated September 27, 2003; PART A: HONEY; II. Typical Composition, a Table with a typical honey composition is shown. References in this document contain the compositions and characteristics of honey in America.

    features
     twenty
    Eucalyptus honey has balsamic, expectorant, antiseptic and anti-inflammatory properties. It is a substance for use in the treatment of bronchitis, colds, pharyngitis, cough, sinusitis, asthma and influenza, and urinary tract diseases, such as cystitis, nephritis and kidney stones. This substance does not contain eucalyptus oil.
     25
    Multiflora honey (97%) with propolis (3%) is a substance for use as an antibacterial, antiviral, antifungal, antiparasitic, analgesic, anti-inflammatory, healing (antiulcer), antioxidant, immunostimulator, anticancer, and in disease treatment prostate.
     30
    White willow honey is a substance for use as an analgesic, antipyretic, anti-inflammatory, anticoagulant, tranquilizer, sedative, astringent, depurative, infectious, and in treatments for skin, burns and wound healing, preventing their infection.
     35
    Invention proposal

    Our proposal for the invention of a composition, for use as a medicine in the actions and treatments of diseases and regeneration of human body tissues, "comprises" 4-methylimidazole (4-MEI), which is used diluted in an aqueous medium , with carbonated water, eucalyptus honey, multiflora honey (97%) with propolis (3%) and white willow honey. This composition can also be used for use as a medicine, as a cream, in topical treatments of skin diseases and in internal treatments using special devices.
     Four. Five
    Thus, our preferred invention proposal is characterized in that the composition "comprises":

    - 4-methylimidazole 26 - 390 micrograms
     fifty
    - Eucalyptus honey 10 - 13 grams

    - Multiflora honey (97%) with propolis (3%) 10 - 13 grams

    - White willow honey 4 - 6 grams

    - Carbonated water 957 - 967 grams (as excipient)

    for use as a medicine in the actions and treatments of the diseases mentioned in this report.

    The preservatives, colorants, flavorings, flavorings and acidifiers, will comply with all the legal requirements of each country in use.
     10
    You can make use of this composition with the content cited for use as a drink during illness, and also for use as a preventive.

    The total weight of all the ingredients mentioned refers to the daily guideline dose for a "standard" adult, divided into four doses, applied every six hours. fifteen

    In case of patients with sugar problems there are limitations. The hypersensitivity to the components, incompatibilities with other compositions, the health conditions of the patient and the age of the children, among others, should be considered. In any case, the doctor must make a prior assessment. twenty
    权利要求:
    Claims (1)
    [1]

    1. A composition for use in the healing of diseases and regeneration of human body tissues comprising the following ingredients:
     5
    - 4-methylimidazole 26 - 390 micrograms
    - Eucalyptus honey 10 - 13 grams
    - Multiflora honey with propolis 10 - 13 grams 10
    - White willow honey 4 - 6 grams
    - Carbonated water 957 - 967 grams (as excipient)
    类似技术:
    公开号 | 公开日 | 专利标题
    Sevgi et al.2013|Topical antimicrobials for burn infections–an update
    A Johnson et al.2013|Evidence for anti-cancer properties of blueberries: a mini-review
    Yang et al.2020|Antimicrobial and anticancer applications and related mechanisms of curcumin-mediated photodynamic treatments
    Vanderzwalmen et al.2019|The use of feed and water additives for live fish transport
    CN105125574A|2015-12-09|Formula and preparation process of polyhexamethylene guanidine drug powder for beasts and birds
    Elshama2018|The preventive role of Arabic gum in the treatment of toxicity
    ES2685077B1|2019-04-02|Composition of 4-methylimidazole for use in the cure of diseases
    CN101279967B|2010-11-10|Medicinal composition of trimethyl xanthone-4-acetic acid for treating cancer and use thereof
    WO2019125128A1|2019-06-27|Use of nutraceutical formulations to produce food supplements for the animal industry, which use natural substances such as minerals, botanical products, essential oils and vitamins with bacteria and enzymes
    RU2013133998A|2015-01-27|METHODS AND COMPOSITIONS FOR PREVENTION AND TREATMENT OF OSTEOARTHRITIS
    ES2758674T3|2020-05-06|Use of taurine in the prevention and / or treatment of diseases induced by viruses of the genus coronavirus and / or of the genus rotavirus
    US10548873B2|2020-02-04|Plant phenols and their use in the treatment or prevention of eosinophilic esophagitis
    WO2021039554A1|2021-03-04|Cancer chemotherapy supporting agent, food, and drug
    AU2014322996B2|2019-12-12|Cocoa polyphenols and their use in the treatment or prevention of eosinophilic esophagitis
    US11167002B2|2021-11-09|Pharmaceutical composition for the treatment of malignant neoplasms including sarcoma, cancers of liver, lung, bladder, blood and cervical, treatment of infectious diseases and type 2 diabetes
    ES2537841B1|2016-05-09|Preparation made from a synergistic combination of polyphenols with antibiotic activity
    ES2750632T3|2020-03-26|Using a particular propolis extract to fight the side effects of chemotherapies
    Nwaopara et al.2009|Histological signs of oligodendroglioma in the brain of rats fed with diet containing Yaji: the complex Nigerian suya meat sauce
    ES2581180A1|2016-09-01|Use of aloe oral for hair improvement |
    Shahagadkar et al.2021|Berry derived constituents in suppressing viral infection: Potential avenues for viral pandemic management
    CN105876110A|2016-08-24|Traditional Chinese medicine additive for meat chicken breeding
    JP2021161105A|2021-10-11|Composition for preventing or treating chronic or acute virus infection and/or sepsis in humans or animals
    Kumar et al.2019|The effect of cranberry fruit extract on alpha-synuclein protein expression using immunostaining techniques.
    CN105832714B|2020-01-10|Application of taurine in preventing and/or treating diseases caused by coronavirus and/or rotavirus viruses
    Shahcheraghi et al.2019|Inhibitory effects of curcumin on sequel of infections and their signaling pathways: a review
    同族专利:
    公开号 | 公开日
    ES2685077B1|2019-04-02|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    法律状态:
    2018-10-05| BA2A| Patent application published|Ref document number: 2685077 Country of ref document: ES Kind code of ref document: A1 Effective date: 20181005 |
    2019-04-02| FG2A| Definitive protection|Ref document number: 2685077 Country of ref document: ES Kind code of ref document: B1 Effective date: 20190402 |
    优先权:
    申请号 | 申请日 | 专利标题
    ES201700370A|ES2685077B1|2017-03-31|2017-03-31|Composition of 4-methylimidazole for use in the cure of diseases|ES201700370A| ES2685077B1|2017-03-31|2017-03-31|Composition of 4-methylimidazole for use in the cure of diseases|
    [返回顶部]